First Time Loading...

Intercept Pharmaceuticals Inc
NASDAQ:ICPT

Watchlist Manager
Intercept Pharmaceuticals Inc Logo
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Watchlist
Price: 19 USD
Updated: Mar 29, 2024

Intrinsic Value

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. [ Read More ]

The intrinsic value of one ICPT stock under the Base Case scenario is 22.75 USD. Compared to the current market price of 19 USD, Intercept Pharmaceuticals Inc is Undervalued by 16%.

Key Points:
ICPT Intrinsic Value
Base Case
22.75 USD
Undervaluation 16%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Intercept Pharmaceuticals Inc

Backtest ICPT Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ICPT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Intercept Pharmaceuticals Inc's business.

What risks and challenges
does Intercept Pharmaceuticals Inc face in the near future?

Summarize the latest earnings report
of Intercept Pharmaceuticals Inc.

Provide P/E
for Intercept Pharmaceuticals Inc and its competitors.

Financials

Balance Sheet Decomposition
Intercept Pharmaceuticals Inc

Current Assets 383.4m
Cash & Short-Term Investments 322.7m
Receivables 32.5m
Other Current Assets 28.3m
Non-Current Assets 9.7m
PP&E 5.8m
Other Non-Current Assets 3.9m
Current Liabilities 90.8m
Accounts Payable 10.3m
Accrued Liabilities 39m
Other Current Liabilities 41.6m
Non-Current Liabilities 230.5m
Long-Term Debt 223.9m
Other Non-Current Liabilities 6.6m
Efficiency

Earnings Waterfall
Intercept Pharmaceuticals Inc

Revenue
317.7m USD
Cost of Revenue
-632k USD
Gross Profit
317.1m USD
Operating Expenses
-372.1m USD
Operating Income
-55.1m USD
Other Expenses
-6.5m USD
Net Income
-61.6m USD

Free Cash Flow Analysis
Intercept Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ICPT Profitability Score
Profitability Due Diligence

Intercept Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
25/100
Profitability
Score

Intercept Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ICPT Solvency Score
Solvency Due Diligence

Intercept Pharmaceuticals Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
45/100
Solvency
Score

Intercept Pharmaceuticals Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ICPT Price Targets Summary
Intercept Pharmaceuticals Inc

Wall Street analysts forecast ICPT stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ICPT is 19 USD .

Lowest
Price Target
Not Available
Average
Price Target
19 USD
0% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ICPT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ICPT Price
Intercept Pharmaceuticals Inc

1M 1M
-
6M 6M
+2%
1Y 1Y
+38%
3Y 3Y
-15%
5Y 5Y
-83%
10Y 10Y
-94%
Annual Price Range
19
52w Low
9.17
52w High
19.29
Price Metrics
Average Annual Return -36.19%
Standard Deviation of Annual Returns 41.53%
Max Drawdown -93%
Shares Statistics
Market Capitalization 794.4m USD
Shares Outstanding 41 826 000
Percentage of Shares Shorted 25.19%

ICPT Return Decomposition
Main factors of price return

What is price return decomposition?

ICPT News

Other Videos

Last Important Events
Intercept Pharmaceuticals Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Intercept Pharmaceuticals Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Intercept Pharmaceuticals Inc Logo
Intercept Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

794.4m USD

Dividend Yield

0%

Description

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 437 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.

Contact

NEW JERSEY
Morristown
305 MADISON AVENUE
+16467471000.0
http://www.interceptpharma.com/

IPO

2012-10-11

Employees

437

Officers

Pres, CEO & Director
Mr. Jerome B. Durso
Chief Financial Officer
Mr. Andrew Saik
Chief Accounting Officer & Treasurer
Mr. Rocco Venezia
Gen. Counsel
Mr. Jared M. Freedberg J.D.
Pres of R&D and Chief Medical Officer
Dr. M. Michelle Berrey M.D., M.P.H., MPH.
Exec. Director of Global Investor Relations
Mr. Nareg Sagherian
Show More
Chief HR Officer
Mr. David Ford
Founder, Advisor & Director
Dr. Mark Pruzanski M.D.
Exec. VP & Chief Commercial Officer
Ms. Linda M. Richardson
Sr. VP of Regulatory Affairs
Paul Nitschmann
Show Less

See Also

Discover More
What is the Intrinsic Value of one ICPT stock?

The intrinsic value of one ICPT stock under the Base Case scenario is 22.75 USD.

Is ICPT stock undervalued or overvalued?

Compared to the current market price of 19 USD, Intercept Pharmaceuticals Inc is Undervalued by 16%.